Editor's Pick
9.0/ 10
TrimRx
Best for best overall value
“Both semaglutide and tirzepatide available”
$199/month
- Compounded
- Semaglutide
WLR
Independent Editorial Rankings
Find the best
weight loss provider for you
We independently rank GLP-1 telehealth providers, weight loss programs, and the pharmacies behind them — so you can save money without falling for sketchy ads.
Reader-supported. When you sign up with a provider through our links we may earn a commission at no extra cost to you. How we make money.
Independent Editorial155+ Providers TrackedUpdated DailyReader-SupportedEvidence-BasedTransparent PricingVerified ReviewsIndependent Editorial155+ Providers TrackedUpdated DailyReader-SupportedEvidence-BasedTransparent PricingVerified Reviews
Why readers use us
Readers save $13,500+/year on weight loss medication.
Brand-name Wegovy retails for around $1,349/month without insurance. The median compounded semaglutide provider in our dataset charges $189/month— same active ingredient, same weekly injection, a fraction of the cost.
Cheapest first-month rate currently in our dataset: $49/mo. Introductory pricing varies by provider and typically increases after the first month — always verify on the provider's site before signing up.
Quick Match
Find your provider in 30 seconds
Three questions. We'll instantly show you the highest-rated provider that matches your budget, state, and preference — based on real pricing data.
Step 1 of 3 · Your budget
What's your monthly budget?
Top Rated
Our picks for 2026
8.6/ 10
Enhance MD
Best for lab-monitored compounded GLP-1 with mandatory video visit
$49/mo
8.5/ 10
Embody
Best for lowest first-month entry pricing on compounded GLP-1s
$99/mo
Browse all 155 editorial reviews
Every provider in our dataset has a first-party editorial review with a six-dimension score, verified pricing, state coverage, and primary-source citations. Read what we found before signing up.
Free Tools to Save You Money
Use our savings calculator to see what you could pay — then compare providers side by side to find the best deal.
GLP-1 Dose Plotter
Interactive pharmacokinetic simulator showing how semaglutide, tirzepatide, and Foundayo (orforglipron) build up across the standard FDA titration schedule.
Find providers in your state
Coverage Map
GLP-1 telehealth providers in every state
Click any state to see the providers that ship and prescribe there. Darker squares mean more provider options available.
Fewer
More
Coverage data compiled from 155 GLP-1 telehealth providers tracked by Weight Loss Rankings.
Editorial flagship
Latest Research
Primary-source deep-dives on GLP-1 weight-loss medications, every claim cited from FDA prescribing information and PubMed.
- Scientific deep-dive14 min · 11 sources
Exercise on a GLP-1: Pilates, Walking, HIIT, and Resistance Training for Lean Mass Preservation
12,700+ monthly searches ask which exercise modalities work for weight loss — pilates, yoga, walking, running, HIIT, strength training. We walk through the GLP-1-specific evidence anchored on the S-LiTE trial (Lundgren NEJM 2021), the Cava 2017 lean mass preservation review, ACSM position stands, and the Saint-Maurice 2020 step count cohort, and explain why resistance training plus protein is the single highest-leverage intervention for GLP-1 patients.
Read the analysis→ - Scientific deep-dive14 min · 11 sources
Metformin and Non-GLP-1 Diabetes Drugs for Weight Loss: What the Trials Actually Show
26,000+ monthly searches ask whether metformin causes weight loss. The DPP, DPPOS 15-year follow-up, ADOPT, and Seifarth 2013 trials show metformin produces ~2-3 kg over 1-2 years and ~5.6% over 6 months in non-diabetic obesity — real but modest, and roughly 1/5 the magnitude of semaglutide and 1/7 of tirzepatide. Here is the verified evidence with PMIDs.
Read the analysis→ - Scientific deep-dive14 min · 11 sources
Topamax, Qsymia, and Topiramate for Weight Loss: What the Trials Actually Show
7,600+ monthly searches ask about topiramate dosing for weight loss. Anchored on Bray 2003 (-6.3% at 192-384 mg), Astrup 2004 (-16.5% at 192 mg maintenance), the Qsymia Phase 3 program (CONQUER -10.2 kg, EQUIP -10.9%, SEQUEL 108-week -12.1%), and the FDA label including the cognitive 'dopamax' side effect, kidney stone risk, metabolic acidosis, and the cleft palate teratogenicity that mandates the REMS program.
Read the analysis→
Get the Free GLP-1 Starter Guide
Plus weekly price alerts and new provider reviews.